Abstract
Rheumatoid arthritis is chronic systemic inflammatory disease that is characterized by joint swelling and leukocyte recruitment into synovial tissue. Within the peripheral blood and synovial fluid of patients with rheumatoid arthritis there are many soluble mediators that function together to create an inflammatory environment ultimately responsible for the synovial pannus formation and subsequent joint destruction. One such group of soluble mediators present in the peripheral blood and synovial fluid of rheumatoid arthritic patients are soluble adhesion molecules. Soluble adhesion molecules are commonly formed as the result of cell surface adhesion molecule shedding due to cell stimulation, but may also be the result of de novo synthesis of truncated soluble forms of adhesion molecules. There has been debate over the function of soluble adhesion molecules in the inflammatory process. Soluble adhesion molecules have been shown to both enhance and inhibit different aspects of the inflammatory process. However, the preponderance of research studying rheumatoid arthritis has shown soluble adhesion molecules to be important regulators of leukocyte recruitment into the synovial tissue. This review will focus on the soluble adhesion molecules that have been studied in peripheral blood and synovial fluids of patients with rheumatoid arthritis. The role of different soluble adhesion molecules in the pathogenesis of rheumatoid arthritis will be discussed, as will the effects of common disease modifying anti-rheumatic therapies on their production.
Keywords: soluble adhesion molecules, adhesion molecules, rheumatoid arthritis, synovial fluid, therapy
Current Pharmaceutical Design
Title: Soluble Adhesion Molecules in the Pathogenesis of Rheumatoid Arthritis
Volume: 11 Issue: 5
Author(s): Michael V. Volin
Affiliation:
Keywords: soluble adhesion molecules, adhesion molecules, rheumatoid arthritis, synovial fluid, therapy
Abstract: Rheumatoid arthritis is chronic systemic inflammatory disease that is characterized by joint swelling and leukocyte recruitment into synovial tissue. Within the peripheral blood and synovial fluid of patients with rheumatoid arthritis there are many soluble mediators that function together to create an inflammatory environment ultimately responsible for the synovial pannus formation and subsequent joint destruction. One such group of soluble mediators present in the peripheral blood and synovial fluid of rheumatoid arthritic patients are soluble adhesion molecules. Soluble adhesion molecules are commonly formed as the result of cell surface adhesion molecule shedding due to cell stimulation, but may also be the result of de novo synthesis of truncated soluble forms of adhesion molecules. There has been debate over the function of soluble adhesion molecules in the inflammatory process. Soluble adhesion molecules have been shown to both enhance and inhibit different aspects of the inflammatory process. However, the preponderance of research studying rheumatoid arthritis has shown soluble adhesion molecules to be important regulators of leukocyte recruitment into the synovial tissue. This review will focus on the soluble adhesion molecules that have been studied in peripheral blood and synovial fluids of patients with rheumatoid arthritis. The role of different soluble adhesion molecules in the pathogenesis of rheumatoid arthritis will be discussed, as will the effects of common disease modifying anti-rheumatic therapies on their production.
Export Options
About this article
Cite this article as:
Volin V. Michael, Soluble Adhesion Molecules in the Pathogenesis of Rheumatoid Arthritis, Current Pharmaceutical Design 2005; 11 (5) . https://dx.doi.org/10.2174/1381612053381972
DOI https://dx.doi.org/10.2174/1381612053381972 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TNFα Modulation of Visceral and Spinal Sensory Processing
Current Pharmaceutical Design Rho Kinase Inhibitors and Novel Ocular Drug Delivery Systems- A Revolutionary Step Towards the Treatment of Glaucoma
Current Drug Delivery COX-2: Friend or Foe?
Current Pharmaceutical Design Ethosomes and its Applications in Transdermal Drug Delivery
Current Drug Therapy B-Cell Based Gene Therapy for Autoimmune Diseases
Infectious Disorders - Drug Targets Anti-Aging Property of G2013 Molecule as a Novel Immunosuppressive Agent on Enzymatic and Non-Enzymatic Oxidative Stress Determinants in Rat Model
Current Drug Discovery Technologies The Urokinase Plasminogen Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective Therapeutic Targets
Current Drug Targets US Guided Treat-to-Target Approach in Early RA: Implications for Uncoupling of Disease Activity and Structural Joint Damage
Current Rheumatology Reviews CENPA a Genomic Marker for Centromere Activity and Human Diseases
Current Genomics Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design TNF-Related Apoptosis-Inducing Ligand (TRAIL) as a Pro-Apoptotic Signal Transducer with Cancer Therapeutic Potential
Current Pharmaceutical Design Molecular Players at the Intersection of Obesity and Osteoarthritis
Current Drug Targets HIV: A Raft-Targeting Approach for Prevention and Therapy Using Plant-Derived Compounds (Review)
Current Drug Targets Pharmacological and Biological Therapies for Metabolic Bone Disease in Critical Illness: An Integrative Physiology Approach
Current Drug Therapy A Review of the Psychometric Properties and Use of the Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL) in Clinical Research
Current Rheumatology Reviews Painful Peripheral Neuropathies
Current Neuropharmacology Do We Need More Research on Platelet Function in South Asian Immigrants?
Inflammation & Allergy - Drug Targets (Discontinued) The Neuropeptides VIP / PACAP and T Cells: Inhibitors or Activators?
Current Pharmaceutical Design The Yin and Yang of Non-Neuronal α7-Nicotinic Receptors in Inflammation and Autoimmunity
Current Drug Targets NMR Based Metabolomics: An Exquisite and Facile Method for Evaluating Therapeutic Efficacy and Screening Drug Toxicity
Current Topics in Medicinal Chemistry